{"id":4370,"date":"2024-09-24T12:34:51","date_gmt":"2024-09-24T16:34:51","guid":{"rendered":"https:\/\/www.med.unc.edu\/medicine\/hematology\/?page_id=4370"},"modified":"2024-09-24T12:34:51","modified_gmt":"2024-09-24T16:34:51","slug":"malignant-hematology-e-consults","status":"publish","type":"page","link":"https:\/\/www.med.unc.edu\/medicine\/hematology\/patient-care\/e-consults\/malignant-hematology-e-consults\/","title":{"rendered":"Malignant Hematology E-Consults"},"content":{"rendered":"<p style=\"font-weight: 400\">Patients with plasma cell diseases should be managed as indicated below.<\/p>\n<p style=\"font-weight: 400\"><u>Likely low-risk monoclonal gammopathy of uncertain significance:<\/u><\/p>\n<ul>\n<li>Patients within the UNC system with small M-spikes (non-IgM and &lt;1.5 g\/dL), normal or mildly abnormal serum free light chain ratios (&lt;10 and &gt;0.1), and no clinical signs or symptoms to suggest an active plasma cell disorder such as multiple myeloma or amyloidosis, should be referred as an\u00a0e-consult to malignant hematology.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Patients with plasma cell diseases should be managed as indicated below. Likely low-risk monoclonal gammopathy of uncertain significance: Patients within the UNC system with small M-spikes (non-IgM and &lt;1.5 g\/dL), normal or mildly abnormal serum free light chain ratios (&lt;10 and &gt;0.1), and no clinical signs or symptoms to suggest an active plasma cell disorder &hellip; <a href=\"https:\/\/www.med.unc.edu\/medicine\/hematology\/patient-care\/e-consults\/malignant-hematology-e-consults\/\" aria-label=\"Read more about Malignant Hematology E-Consults\">Read more<\/a><\/p>\n","protected":false},"author":112673,"featured_media":0,"parent":4341,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"layout":"","cellInformation":"","apiCallInformation":"","footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-4370","page","type-page","status-publish","hentry","odd"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Malignant Hematology E-Consults - Division of Hematology<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.med.unc.edu\/medicine\/hematology\/patient-care\/e-consults\/malignant-hematology-e-consults\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Malignant Hematology E-Consults - Division of Hematology\" \/>\n<meta property=\"og:description\" content=\"Patients with plasma cell diseases should be managed as indicated below. Likely low-risk monoclonal gammopathy of uncertain significance: Patients within the UNC system with small M-spikes (non-IgM and &lt;1.5 g\/dL), normal or mildly abnormal serum free light chain ratios (&lt;10 and &gt;0.1), and no clinical signs or symptoms to suggest an active plasma cell disorder &hellip; Read more\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.med.unc.edu\/medicine\/hematology\/patient-care\/e-consults\/malignant-hematology-e-consults\/\" \/>\n<meta property=\"og:site_name\" content=\"Division of Hematology\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/hematology\/patient-care\/e-consults\/malignant-hematology-e-consults\/\",\"url\":\"https:\/\/www.med.unc.edu\/medicine\/hematology\/patient-care\/e-consults\/malignant-hematology-e-consults\/\",\"name\":\"Malignant Hematology E-Consults - Division of Hematology\",\"isPartOf\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/hematology\/#website\"},\"datePublished\":\"2024-09-24T16:34:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/hematology\/patient-care\/e-consults\/malignant-hematology-e-consults\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.med.unc.edu\/medicine\/hematology\/patient-care\/e-consults\/malignant-hematology-e-consults\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/hematology\/patient-care\/e-consults\/malignant-hematology-e-consults\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.med.unc.edu\/medicine\/hematology\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Patient Care\",\"item\":\"https:\/\/www.med.unc.edu\/medicine\/hematology\/patient-care\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"E-Consults\",\"item\":\"https:\/\/www.med.unc.edu\/medicine\/hematology\/patient-care\/e-consults\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Malignant Hematology E-Consults\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/hematology\/#website\",\"url\":\"https:\/\/www.med.unc.edu\/medicine\/hematology\/\",\"name\":\"Division of Hematology\",\"description\":\"Department of Medicine\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.med.unc.edu\/medicine\/hematology\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Malignant Hematology E-Consults - Division of Hematology","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.med.unc.edu\/medicine\/hematology\/patient-care\/e-consults\/malignant-hematology-e-consults\/","og_locale":"en_US","og_type":"article","og_title":"Malignant Hematology E-Consults - Division of Hematology","og_description":"Patients with plasma cell diseases should be managed as indicated below. Likely low-risk monoclonal gammopathy of uncertain significance: Patients within the UNC system with small M-spikes (non-IgM and &lt;1.5 g\/dL), normal or mildly abnormal serum free light chain ratios (&lt;10 and &gt;0.1), and no clinical signs or symptoms to suggest an active plasma cell disorder &hellip; Read more","og_url":"https:\/\/www.med.unc.edu\/medicine\/hematology\/patient-care\/e-consults\/malignant-hematology-e-consults\/","og_site_name":"Division of Hematology","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.med.unc.edu\/medicine\/hematology\/patient-care\/e-consults\/malignant-hematology-e-consults\/","url":"https:\/\/www.med.unc.edu\/medicine\/hematology\/patient-care\/e-consults\/malignant-hematology-e-consults\/","name":"Malignant Hematology E-Consults - Division of Hematology","isPartOf":{"@id":"https:\/\/www.med.unc.edu\/medicine\/hematology\/#website"},"datePublished":"2024-09-24T16:34:51+00:00","breadcrumb":{"@id":"https:\/\/www.med.unc.edu\/medicine\/hematology\/patient-care\/e-consults\/malignant-hematology-e-consults\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.med.unc.edu\/medicine\/hematology\/patient-care\/e-consults\/malignant-hematology-e-consults\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.med.unc.edu\/medicine\/hematology\/patient-care\/e-consults\/malignant-hematology-e-consults\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.med.unc.edu\/medicine\/hematology\/"},{"@type":"ListItem","position":2,"name":"Patient Care","item":"https:\/\/www.med.unc.edu\/medicine\/hematology\/patient-care\/"},{"@type":"ListItem","position":3,"name":"E-Consults","item":"https:\/\/www.med.unc.edu\/medicine\/hematology\/patient-care\/e-consults\/"},{"@type":"ListItem","position":4,"name":"Malignant Hematology E-Consults"}]},{"@type":"WebSite","@id":"https:\/\/www.med.unc.edu\/medicine\/hematology\/#website","url":"https:\/\/www.med.unc.edu\/medicine\/hematology\/","name":"Division of Hematology","description":"Department of Medicine","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.med.unc.edu\/medicine\/hematology\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links_to":[],"_links_to_target":[],"_links":{"self":[{"href":"https:\/\/www.med.unc.edu\/medicine\/hematology\/wp-json\/wp\/v2\/pages\/4370","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.med.unc.edu\/medicine\/hematology\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.med.unc.edu\/medicine\/hematology\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/hematology\/wp-json\/wp\/v2\/users\/112673"}],"replies":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/hematology\/wp-json\/wp\/v2\/comments?post=4370"}],"version-history":[{"count":0,"href":"https:\/\/www.med.unc.edu\/medicine\/hematology\/wp-json\/wp\/v2\/pages\/4370\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/hematology\/wp-json\/wp\/v2\/pages\/4341"}],"wp:attachment":[{"href":"https:\/\/www.med.unc.edu\/medicine\/hematology\/wp-json\/wp\/v2\/media?parent=4370"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}